Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.
Study Type
OBSERVATIONAL
Enrollment
100
Washington University School of Medicine
St Louis, Missouri, United States
RECRUITINGFreedom from progression
-Defined as RECIST 1.1 based radiographic or clinical progression, with non-progressors censored at last radiographic follow-up
Time frame: Through completion of study (estimated to be 6.5 years)
Event-free survival
-Defined as post-treatment ctDNA detection or RECIST 1.1 based radiographic progression
Time frame: Through completion of study (estimated to be 6.5 years)
Disease-specific survival
-Defined as death from cancer
Time frame: Through completion of study (estimated to be 6.5 years)
Overall survival
-Defined as death from any cause
Time frame: Through completion of study (estimated to be 6.5 years)
Pathologic complete response rate
Time frame: Through completion of study (estimated to be 6.5 years)
Locoregional failure
-Defined as clinical or radiographic progression within the localized tumor/treatment area or regional lymph nodes
Time frame: Through completion of study (estimated to be 6.5 years)
Distant-metastasis-free survival
-Defined as clinical or radiographic progression outside the localized tumor/treatment area and regional lymph nodes
Time frame: Through completion of study (estimated to be 6.5 years)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.